Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06687603 · ClinicalTrials.gov registry record · NA
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
A NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 5
- Study locations
NCT06687603 is a NA study of Esophageal Adenocarcinoma and Barrett Esophagus that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 800 participants, above the 290-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (176% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT06687603, a NA study of Esophageal Adenocarcinoma and Barrett Esophagus, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. The main question it aims to answer is: Can this approach demonstrate efficacy for screening of Barrett's esophagus? Participants will: * Participate in a questionnaire. * Undergo a capsule balloon test, called EsoCheck. * Have their EsoCheck sample sent to the laboratory for an EsoGuard test, which is used to detect Barrett's esophagus. * Participants will undergo upper endoscopy as part of standard of care.
Conditions Studied
Interventions
- DEVICE EsoCheck
- DIAGNOSTIC_TEST EsoGuard
Study Locations (5)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Cleveland Clinic Taussig Cancer Center - Cleveland
Colorado
- University of Colorado - Aurora
Maryland
- Johns Hopkins Hospital - Baltimore
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2029-09-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06687603
The ClinicalTrials.gov registry entry for NCT06687603 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 290-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (176% higher). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which EsoCheck is the first listed.
NCT06687603 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT06687603 about?
NCT06687603 is a clinical study titled "Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms". The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged ...
What is the current status of trial NCT06687603?
This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2025-03-10. Estimated completion is 2029-09-27.
What conditions does trial NCT06687603 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Gastroesophageal Reflux.
What interventions are being tested in trial NCT06687603?
The interventions under investigation include: EsoCheck (DEVICE), EsoGuard (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06687603?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06687603 being conducted?
This trial has 5 study locations across Colorado, Maryland, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.